Zymeworks Inc.
NASDAQ:ZYMEBiotechnology
Healthcare
$26.86 -1.64%
-$0.38 today
- Market cap
- $1.87B
- Beta
- 1.14
- P/E (TTM)
- -16.6
- EPS (TTM)
- -$1.37
52W Low $11.51High $29.75
Volume 0.99M
Average 0.71M
Income Statement
Follow revenue through to earnings.
Revenue
$105.97M
FY 2025 · Annual
+38.9% YoYOperating Income
-$92.53M
FY 2025 · Annual
Net Income
-$81.13M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 26.68M | 412.48M | 76.01M | 76.3M | 105.97M |
| Cost of Revenue | 0 | 0 | 142.99M | 0 | 0 |
| Gross Profit | 26.68M | 412.48M | (66.98M) | 76.3M | 105.97M |
| Gross Margin | 100.0% | 100.0% | -88.1% | 100.0% | 100.0% |
| Research & Development | 199.75M | 208.6M | 143.62M | 134.62M | 137M |
| Selling, General & Admin | 42.6M | 73.4M | 70.4M | 61.5M | 61.5M |
| Operating Expenses | 242.31M | 281.95M | 71.08M | 213.41M | 198.5M |
| Depreciation & Amortization | 9.58M | 12M | 17.31M | 11.19M | 11.11M |
| EBITDA | (206.09M) | 142.49M | (120.7M) | (108.62M) | (68.64M) |
| EBITDA Margin | -772.4% | 34.5% | -158.8% | -142.4% | -64.8% |
| Operating Income | (215.63M) | 130.53M | (138.05M) | (137.11M) | (92.54M) |
| Operating Margin | -808.2% | 31.6% | -181.6% | -179.7% | -87.3% |
| Interest Income | 1.97M | 3.6M | 19.71M | 19.94M | 13.35M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 3.27M | 4.71M | 18.81M | 20.5M | 12.78M |
| Income Before Tax | (212.36M) | 135.23M | (119.24M) | (116.61M) | (79.75M) |
| Pre-Tax Margin | -795.9% | 32.8% | -156.9% | -152.8% | -75.3% |
| Income Tax Expense | (516K) | 10.89M | (568K) | 6.08M | 1.38M |
| Net Income | (211.84M) | 124.34M | (118.67M) | (122.7M) | (81.13M) |
| Net Margin | -794.0% | 30.1% | -156.1% | -160.8% | -76.6% |
| EPS (Basic) | (4.06) | 1.91 | (1.72) | (1.62) | (1.08) |
| EPS (Diluted) | (4.61) | 1.90 | (1.72) | (1.62) | (1.08) |
| 52.13M | 65.19M | 68.86M | 75.85M | 75.34M | |
| 52.13M | 65.25M | 68.86M | 75.88M | 75.34M |
ZYME Earnings Waterfall · TTM
NASDAQ:ZYME · Revenue to Net Income
Key Ratios
EPS$0.52
Gross Margin45.9%
Net Margin-1096.4%
P/E Ratio-7.6
P/S Ratio497.1
Analysis
$266.0M of revenue converted into $43.3M of net income for the selected period. Gross margin is 45.9% and net margin is -1096.4%, showing how much revenue survives after costs and taxes. EPS is $0.52, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 9, 2026 | |
| 8-K/A | 8-K/A filing | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| ARS | ARS filing | Oct 26, 2026 | |
| DEFA14A | DEFA14A filing | Oct 26, 2026 |
How much revenue does ZYME generate?
Zymeworks Inc. (ZYME) reported $105.97M of revenue in fiscal 2025.
Is ZYME profitable?
Zymeworks Inc. (ZYME) reported -$81.13M of net income, with a net margin of -76.6%.
Continue the stock analysis
Jump to another research area for this company.